CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD204, a Lutetium-177 Radiolabelled Single Domain Antibody Against Programmed Cell Death-Ligand 1 in Patients With Metastatic Solid Tumours

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06305962
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:23.318439+00:00
Published At: 2026-02-19T00:00:00+00:00
Record Updated At: 2026-02-19
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["PDL1 Gene Mutation", "Non Small Cell Lung Cancer", "Small Cell Lung Cancer ( SCLC )", "TNBC, Triple Negative Breast Cancer", "Cutaneous Melanoma", "HNSCC", "Endometrial Cancer", "Mmr Deficiency", "MSI-High"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-02-19"
protocolSection.identificationModule.nctId: "NCT06305962"
protocolSection.identificationModule.officialTitle: "Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD204, a Lutetium-177 Radiolabelled Single Domain Antibody Against Programmed Cell Death-Ligand 1 in Patients With Metastatic Solid Tumours"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["EARLY_PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.